Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pre-Open Movers 12/09: (THOR) (XBIT) (ARQL) Higher (DPLO) (THO) (M) Lower (more...)

Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh

December 11, 2019 5:59 AM EST

Rocket Pharmaceuticals, Inc. (NASDAQ:... More

Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering

December 10, 2019 4:02 PM EST

Rocket... More

Agios Pharma (AGIO) Reports Updated Data for Mitapivat from Extension Phase of DRIVE PK Study in Patients with Pyruvate Kinase Deficiency

December 9, 2019 10:13 AM EST

Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) today reported new data from the extension phase of the DRIVE PK Phase 2 study of mitapivat (AG-348) in adults with pyruvate kinase (PK) deficiency at the 2019 American Society of Hematology (ASH) Annual Meeting. Mitapivat is an investigational, first-in-class, oral, small molecule allosteric activator of wild-type and a variety of mutated pyruvate kinase-R (PKR) enzymes that directly targets the underlying metabolic defect in PK deficiency, a rare, potentially debilitating, hemolytic anemia. In addition, data was shared from the Agios-sponsored Natural History Study of PK deficiency that detailed the comorbidities and... More